Pfizer

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on: 
Friday, August 19, 2022 - 3:00pm

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .

Key Points: 
  • To view and listen to the webcast, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
  • Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Arvinas Announces Changes to its Board of Directors

Retrieved on: 
Thursday, August 18, 2022 - 9:01pm

On behalf of my fellow Board members and Arvinas leadership team, I would like to thank Liam for his dedication and impactful contributions.

Key Points: 
  • On behalf of my fellow Board members and Arvinas leadership team, I would like to thank Liam for his dedication and impactful contributions.
  • Mr. Young joins Arvinas Board with nearly 35 years of experience with Pfizer.
  • John is an exceptional leader with deep experience and a strong track record in the pharmaceutical industry, and I am pleased to welcome him to Arvinas Board of Directors, said Dr. Houston.
  • I am extremely impressed with the tremendous work Arvinas is doing in the targeted protein degradation space, added Mr. Young.

DGAP-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Retrieved on: 
Thursday, August 18, 2022 - 12:07pm

In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.

Key Points: 
  • In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.
  • Moving into the second half of 2022, we are further broadening our mRNA technology platform and advancing our programs in prophylactic vaccines as well as executing on our core strategy in oncology.
  • CureVac is delivering on its previously announced 2022 clinical development program in prophylactic vaccines by initiating a Phase 1 study with the modified COVID-19 mRNA vaccine candidate CV0501.
  • In the first quarter of 2022, CureVac received a 10 million milestone payment related to the start of the seasonal influenza clinical trial.

Alation Welcomes Tim Harford OBE as Keynote Speaker at revAlation in London

Retrieved on: 
Thursday, August 18, 2022 - 8:00am

Tim Harford is a bestselling author of books about economics and data, and the writer of the award-winning Financial Times column, The Undercover Economist.

Key Points: 
  • Tim Harford is a bestselling author of books about economics and data, and the writer of the award-winning Financial Times column, The Undercover Economist.
  • Harford will keynote the event and discuss how to use data and economics in everyday life.
  • revAlation will bring together data professionals in-person to showcase how Alation can help organisations drive data culture .
  • Attendees will learn to use specific tools, techniques, and tips to master Active Data Governance using Alation Data Catalog .

6-Hour Virtual Seminar on Combination Products - Webinar - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 5:18pm

Salma Michor, PhD, MSc, MBA, CMgr, RAC is founder and CEO of Michor Consulting Schweiz GmbH, serving such clients as Johnson & Johnson, Novartis, Shire, Pfizer and Colgate Palmolive.

Key Points: 
  • Salma Michor, PhD, MSc, MBA, CMgr, RAC is founder and CEO of Michor Consulting Schweiz GmbH, serving such clients as Johnson & Johnson, Novartis, Shire, Pfizer and Colgate Palmolive.
  • Previously, Michor worked for Chiesi-Torrex, Wyeth Whitehall Export Croma Pharma GmbH.
  • She teaches regulatory affairs and clinical strategies at the University of Krems, Austria, and is an independent expert to the European Commission.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005604/en/

Cannabis Testing Services Market by Test Type, Product Type, End-users, and Region - Global Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 1:53pm

The "Cannabis Testing Services Market, by Test Type, by Product Type, by End-users, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabis Testing Services Market, by Test Type, by Product Type, by End-users, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing adoption of inorganic growth strategies such as acquisition by key players is expected to drive the market growth over the forecast period.
  • For instance, in December 2021, Pfizer Inc., multinational pharmaceutical and Biotechnology Corporation had acquired with the clinical-stage company Arena Pharmaceuticals, a Biotech Company.
  • Furthermore, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation had signed agreement for testing analysis with the clinical-stage company Arena Pharmaceuticals for a total equity value of around $6.7 billion.

Kriya Appoints Pedro Huertas M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division

Retrieved on: 
Wednesday, August 17, 2022 - 1:15pm

Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, announced today that it has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division.

Key Points: 
  • Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, announced today that it has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division.
  • In his role, Dr. Huertas will be responsible for the direction and execution of the companys clinical, medical and scientific plans to advance its rare disease pipeline.
  • Prior to joining Kriya, Dr. Huertas served as Chief Medical Officer at Inozyme Pharma, Sentien Biotechnologies, and Eloxx Pharmaceuticals.
  • Earlier in his career, Dr. Huertas also held clinical and development roles at Pfizer, Shire, Amicus, and Genzyme Corp.
    Pedro brings a wealth of experience to Kriya as we continue to advance our rare disease gene therapy portfolio, said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya.

Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors

Retrieved on: 
Wednesday, August 17, 2022 - 1:00pm

MELBOURNE, Australia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet medical needs, is pleased to announce the appointment of experienced pharmaceutical executive Mr Robert B. Clark to the Board of Directors.

Key Points: 
  • Mr Clark is a senior-level strategic regulatory affairs expert with over 38 years of US and Global regulatory experience, including >20 years with Pfizer Inc. and >10 years with Novo Nordisk A/S.
  • Mr Clark is Vice President, US Regulatory Affairs for Novo Nordisk where he provides strategic leadership to a team of over 50 regulatory staff and scientists in the development of new medicines.
  • Prior to joining Nova Nordisk, Mr Clark was Vice President of Worldwide Regulatory Strategy and US Regulatory Affairs at Pfizer, leading a team of up to 150 regional regulatory professionals supporting the drug development continuum.
  • Mr Clark has senior level experience in managing regulatory aspects of large-scale pharmaceutical acquisitions, significant compliance matters and business development due diligence activities.

Emery Pharma Announces New Biologics Analytical Division

Retrieved on: 
Wednesday, August 17, 2022 - 1:00pm

ALAMEDA, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Emery Pharma has officially expanded its state-of-the-art laboratories which feature a brand-new High-Resolution Orbitrap Mass Spectrometer, enabling Emery Pharma to expand its service offerings.

Key Points: 
  • ALAMEDA, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Emery Pharma has officially expanded its state-of-the-art laboratories which feature a brand-new High-Resolution Orbitrap Mass Spectrometer, enabling Emery Pharma to expand its service offerings.
  • We are excited for him to lead the new Large Molecule Analytical Division at Emery Pharma," said Dr. Neel Bose, CSO.
  • Emery Pharma is a full-service contract research laboratory, specializing in supporting preclinical drug development, including analytical, bioanalytical solutions, microbiology & cell biology services, drug and impurity characterization, and general R&D and cGMP/GLP support.
  • Emery Pharma is equipped to support the development of small molecule drugs, biologics, biosimilars, gene therapies, botanical drugs, and more.

Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian

Retrieved on: 
Tuesday, August 16, 2022 - 9:05pm

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Kate Hermans as interim Chief Executive Officer, replacing Feng Tian, Ph.D., effective immediately.

Key Points: 
  • Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Kate Hermans as interim Chief Executive Officer, replacing Feng Tian, Ph.D., effective immediately.
  • Ms. Hermans appointment to the role of interim CEO follows her appointment to Ambrxs Board earlier in 2022.
  • Ms. Hermans brings more than two decades of commercial and operational experience in the healthcare industry to Ambrx.
  • Concurrent to Ms. Hermans appointment, Katrin Rupalla, Ph.D., was appointed Chair of the Board of Directors, replacing Dr. Tian.